Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.

“Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study. Masuzaki H(1), Nagashima H(2), Shingaki T(3), Oura T(3), Tatsuno I(4). Author information: (1)Division of Endocrinology and Metabolism, Hematology, Rheumatology; Second Department of Internal Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan. (2)Tokyo Center Clinic, Tokyo, Japan. (3)Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan. (4)Chiba Prefectural University of Health Sciences, Chiba, Japan. AIMS: We evaluated the impact of tirzepatide on health-related quality of life (HR-QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT-J trial. MATERIALS AND METHODS: Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle modifications. Prespecified analyses assessed changes from baseline to Week 72 in HR-QoL using the Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) and 36-Item Short-Form Health Survey Version 2.0 (SF-36v2), and assessed subgroup differences by sex (male, female), baseline body mass index (< 35, ≥ 35 kg/m2) and age (< 65, ≥ 65 years). Post hoc analyses examined correlations between HR-QoL scores and percentage weight loss. RESULTS: Among 201 participants (tirzepatide 10 mg: n = 63; tirzepatide 15 mg: n = 69; placebo: n = 69), both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo. Subgroup analyses showed no major variations in treatment effect by baseline characteristics. Across treatment groups, weight loss was correlated with IWQOL-Lite-CT improvements at Week 72 (r values up to -0.32), with several correlations reaching statistical significance. CONCLUSIONS: In Japanese adults with obesity disease, tirzepatide significantly improved HR-QoL over 72 weeks compared with placebo in both physical and psychosocial domains. These findings align with results from the SURMOUNT clinical program, indicating that tirzepatide may improve HR-QoL across different populations with obesity or overweight. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04844918. © 2026 Eli Lilly Japan K.K and The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”